Phase II Dose Titration Study in Patients With Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00736151
Recruitment Status : Completed
First Posted : August 15, 2008
Last Update Posted : August 7, 2009
Information provided by:
Newron Pharmaceuticals SPA

Brief Summary:
The purpose of this study is to examine the effects of various increasing doses of Ralfinamide in patients with neuropathic pain.

Condition or disease Intervention/treatment Phase
Neuropathic Pain Drug: Ralfinamide Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 272 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Basic Science
Official Title: A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
Study Start Date : May 2004
Actual Primary Completion Date : April 2007

Arm Intervention/treatment
Experimental: 1
Ralfinamide administered orally at rising doses of 80 - 320 mg/day
Drug: Ralfinamide
Oral tablets administered at rising doses of 80 - 320 mg/day

Active Comparator: 2
Placebo controlled with randomization of 2:1
Drug: Ralfinamide
Oral tablets administered at rising doses of 80 - 320 mg/day

Primary Outcome Measures :
  1. Change of pain intensity [ Time Frame: Baseline to week 8 or last visit ]

Secondary Outcome Measures :
  1. The incidence of adverse events [ Time Frame: From baseline to week 8 or last visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients
  • Females post-menopausal for at least 12 months, 24 months in India, Poland, and Austria
  • Diagnosed by neurologist with current neuropathic pain

Exclusion Criteria:

  • See inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00736151

  Hide Study Locations
Universitatsklinik Fur Neurologie
Graz, Austria
Universitatsklinik Fur Neurologie
Innsbruck, Austria
Klagenfurt, Austria
General Hospital AKH
Wien, Austria
Czech Republic
Fakultni nemocnice Brno
Brno-Bhunice, Czech Republic
Fakultni nemocnice u svate' Anny v Brne
Brno, Czech Republic
University Hospital Olomouc
Olomouc, Czech Republic
Univercity Hospital Pilsen
Pizen, Czech Republic
Na Homolce Hospital
Prague, Czech Republic
Fakultni Thomayerova nemocnices poliklinikou
Praha, Czech Republic
Neurology Centre
Ahmedabad, India
M.S. Ramaiah Medical
Bangalore, India
R.S. R'S Trinity Acute Care Hospital
Chennai, India
Sri Ramachandra medical College
Chennai, India
Care Hospital
Hyderabad, India
Chowpatty Medical Centre
Mumbai, India
Brain and Mind Institute
Nagpur, India
Apollo Hospital
Pradesh, India
Brain Waves Clinic
Pune, India
Vijaya Health Centre
Vadapalani, India
Ospedali Riuniti di Bergamo
Bergamo, Italy
Ce. S.I. Fondazione Universitaria
Chieti, Italy
Ospedale Clinicizzato Universitario SS. Annunziata
Chieti, Italy
Arcispedale Sant'Anna
Ferrara, Italy
Azienda Ospedaliera San Martino
Genova, Italy
Universita degli Studi di Genova
Genova, Italy
Ospedale Luigi Sacco
Grassi, Italy
Ospedale Civile Umberto I
Mestre, Italy
Ospedale San Raffaele
Milano, Italy
Istituto Scientifico di Riabilazione di Montescano
Montescano, Italy
Policlinico Universitario Federico II
Napoli, Italy
Pavia, Italy
Presidio Ospedaliero Monteluce
Perugia, Italy
Universita degli Studi di Roma
Roma, Italy
Policlinico G.B. Rossi
Verona, Italy
Centrum Medyczne Osteomed
Bialobrzeska, Poland
Centrum Kliniczno Badawcze
Elblag, Poland
Wojewodzki Szpiyal Spejalistyczny
Gdansk, Poland
Center Of Clinical Neurology
Krakow, Poland
Osrodek Baden Klinicznych
Lublin, Poland
Wojskowy Instytut Medyczny
Warszawa, Poland
Wroclaw Medical University
Wroclaw, Poland
Oddzial Neurologiczny
Zgierz, Poland
United Kingdom
Gartnavel General Hospital
Glasgow, United Kingdom
Barta and The London NHS Trust
London, United Kingdom
Kings College Hospital
London, United Kingdom
Solihull Hospital
West Midlands, United Kingdom
Sponsors and Collaborators
Newron Pharmaceuticals SPA

Responsible Party: Stefano Rossetti, MD, Newron Pharmaceuticals S.p.A Identifier: NCT00736151     History of Changes
Other Study ID Numbers: NW-1029/001/II/2003
EUDRACT Number 2004-000557-35
First Posted: August 15, 2008    Key Record Dates
Last Update Posted: August 7, 2009
Last Verified: August 2009

Additional relevant MeSH terms:
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms